| CCSAX | JCCSX | CCSAX / JCCSX | |
| Total Expense Ratio | 1.11 | 1.42 | 78% |
| Annual Report Gross Expense Ratio | 1.11 | 1.57 | 71% |
| Fund Existence | 14 years | 8 years | - |
| Gain YTD | 37.259 | 30.958 | 120% |
| Front Load | 6% | 6% | 105% |
| Min. Initial Investment | 2000 | 2500 | 80% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 474M | 1.08B | 44% |
| Annual Yield % from dividends | 2.18 | 6.85 | 32% |
| Returns for 1 year | 45.59 | 43.27 | 105% |
| Returns for 3 years | 57.89 | 58.97 | 98% |
| Returns for 5 years | 85.36 | 80.88 | 106% |
| Returns for 10 years | 129.37 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| NASDX | 52.85 | 0.47 | +0.90% |
| Shelton Nasdaq-100 Index Investor | |||
| FCAGX | 38.20 | N/A | N/A |
| Fidelity Advisor Small Cap Growth A | |||
| ACMDX | 11.72 | N/A | N/A |
| Absolute Capital Defender Investor | |||
| ECHSX | 13.21 | N/A | N/A |
| Eaton Vance Worldwide Health Sci C | |||
| SVIIX | 10.48 | N/A | N/A |
| Virtus Ceredex Large-Cap Value Equity A | |||